Chicago, ILNCT06570213Now EnrollingIRB Ready

PTSD Clinical Trial in Chicago, IL

Access cutting-edge ptsd treatment through this early phase 1 clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by Rush University Medical Center

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access ptsd specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related ptsd treatment provided free

Apply for This Chicago Location

Check if you qualify for this ptsd clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This PTSD Study in Chicago

The purpose of this study is to understand if we can improve the treatment for posttraumatic stress disorder (PTSD). We are looking into whether the combination of Stellate Ganglion Block (SGB) treatment and Cognitive Processing Therapy (CPT) can reduce symptoms of PTSD. CPT is a trauma-focused talk therapy that can help identify and challenge unhelpful trauma-related beliefs about oneself, others, and the world. It is known to be a highly effective talk therapy for PTSD. SGB treatment is a procedure involving an injection of local anesthetic into a bundle of nerves located in the neck that is part of the sympathetic nervous system which controls our body's response to stressful situations and blocks pain. The proposed project will systematically test whether combining CPT with SGB produces greater PTSD symptom reductions and functional improvements in the short- and longer-term up to 6-months follow-up compared to CPT (+Placebo) or SGB (+Daily Monitoring) alone.

Sponsor: Rush University Medical Center

Who Can Participate

Inclusion Criteria

Are 18 years or older
Are fluent in English
Have experienced a Criterion A traumatic event during their lifetime
Have a PTSD diagnosis verified via the Clinician Administered PTSD Scale for DSM-5
Have not previously received a Stellate Ganglion Block
Have a smartphone that they can use for the entire duration of the study
Are willing and able to receive 2 injections (SGB or placebo) 2 weeks apart at the Rush Pain Clinic
Are willing and able to participate in daily Cognitive Processing Therapy or Daily Monitoring over the course of one week
Are willing and able to complete self-report measures and clinician-rated assessments at multiple time points over the course of the study

Exclusion Criteria

The traumatic event occurred in the past month
They are currently suicidal or homicidal (i.e., plan and intent)
They have unmanaged psychosis or mania
They have not been on a stable dose of psychotropic medication for at least one month by the time of the baseline assessment or are planning to change their medications within 3 months of starting their participation in the study
They have completed an evidence-based cognitive behavioral PTSD treatment (e.g., Cognitive Processing Therapy or Prolonged Exposure) in the past 3 months or are currently receiving an evidence-based PTSD treatment
They have an intellectual disability or significant cognitive impairment that would prevent them from engaging fully in treatment
They are currently on any blood-thinning medications or have a coagulopathy -They have any of the following conditions: a recent myocardial infarction, glaucoma, a pre- existing contralateral nerve palsy, severe emphysema, or a cardiac conduction blockade.
They are allergic to any of the medications injected (i.e., ropivacaine, lidocaine, propofol)
They have an active infection
They have a serious or unstable medical illness or instability for which hospitalization may be likely within the next year
They have a visual or auditory impairment that would prevent them from fully participating in study activities
They are involved with current legal actions related to the traumatic event that is anticipated to be targeted during treatment
They have substance dependence that, in the judgment of the Principal Investigator, may require hospitalization if substances were discontinued.
Subjects who, at the time of consent, appear to have extenuating life circumstances (e.g., unstable housing, no internet access, etc.) which, in the judgment of the Principal Investigator, could affect the ability to deliver the intervention with fidelity

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT06570213) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

PTSD Treatment Options in Chicago, IL

If you're searching for ptsd treatment options in Chicago, IL, this clinical trial (NCT06570213) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this early phase 1 clinical trial. You'll receive care from experienced ptsd specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all ptsd clinical trials near you to find additional studies recruiting in your area.

More PTSD Trials in Chicago, IL

See all ptsd clinical trials recruiting in Chicago — not just this study.

Browse PTSD Trials in Chicago →

Browse More Trials by Condition

PTSD TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL